Device Registries and Research Grants: When Enrollment Rewards Product Use

Medical device research grants can become kickbacks when manufacturers use them to pay physicians or hospitals to choose their products. The study file describes the clinical work. The sales file may explain why a particular investigator received an invitation. If you manage enrollment, approve research payments or sell the devices, you may see the connection between a payment described as research and a decision to use the manufacturer’s product.

Those activities put manufacturers in regular contact with the physicians who choose their products. A research payment can reach the physician or the hospital itself.

The commercial connection extends to the provider’s claim. The physician chooses the device, the institution buys it, and the provider submits a claim for the procedure. A payment intended to influence that choice can reach Medicare through the hospital’s bill, even when the manufacturer never submits a claim of its own.

When a Research Payment Becomes a Sales Payment

The useful comparison is what the company paid for against what the investigator actually did. A protocol describes the scientific question. The selection records, payment terms and sales correspondence can explain why this customer received the opportunity.

Who proposed the study, and who approved it? How did the company choose the sites and investigators? Was the fee tied to recorded work, patient enrollment or use of a particular device? What data reached the company, who reviewed it, and what happened when the work or the purchasing stopped? We examine those questions together because the research agreement and the sales account may tell different parts of the same story.

For an investigator, the important comparison may be promised research support against the resources actually provided. For a sales representative, it may be the customer list used to recruit participants. For finance, it may be the payment that continued while deliverables stopped, or the payment withheld until a purchase. Each connects the agreement’s stated purpose to a business decision.

Why Are Kickbacks Illegal?

The Anti-Kickback Statute protects medical decisions from payments intended to influence purchases or referrals covered by federal health care programs. In a device case, the decision can be which implant goes into a patient or which equipment a hospital buys. The benefit can be research money, free equipment or another form of value. Patients depend on that choice, taxpayers pay for the procedure, and competing manufacturers can lose business to the payment.

A 2020 analysis of federal healthcare fraud laws in the Journal of Forensic and Investigative Accounting explains the significance of a payment having more than one purpose. The article describes courts treating an intent to induce referrals as sufficient even when that was only one purpose of the payment. For the arrangements here, that directs attention to customer selection and internal sales expectations as well as the scientific work. We connect those facts to the government-paid procedures when evaluating a whistleblower case.

What Are Some Examples of Kickbacks in Healthcare?

Medical device cases have involved fees for enrolling patients, grants held until a purchase, and research arrangements directed at customers using a competitor’s product. The following cases show how the payment, the decision-maker and the resulting business can fit together.

St. Jude Paid Physicians Per Patient

St. Jude Medical agreed to a $16 million settlement in 2011 over allegations that it used post-market studies and a registry to induce implantation of its pacemakers and defibrillators. The Justice Department’s announcement describes three studies and a device registry, with fees reaching $2,000 per patient.

The government alleged that St. Jude solicited physicians to keep their business or move it away from a competitor. That puts investigator recruitment at the center of the case: the opportunity to participate allegedly served the company’s effort to win the physician’s next device choice.

The department expressly acknowledged that St. Jude collected data and information. Its allegation concerned what the company intended the payments to accomplish. A clinical file and a sales file could therefore describe the same participating physician for very different reasons.

Medtronic Required Its Device in Every Enrolled Patient

Medtronic agreed to a $23.5 million settlement later in 2011 over physician payments connected to post-market studies and device registries. According to the government’s account, each study or registry required a new or previous implant of a Medtronic pacemaker or defibrillator in every patient.

The government alleged that Medtronic paid participating physicians per patient and selected them to convert their business from a competitor or persuade them to continue using Medtronic products, causing false claims to Medicare and Medicaid.

The enrollment condition explains the commercial connection. Participation required a Medtronic device. The recruitment strategy allegedly targeted the physicians whose product choices the company wanted to influence.

Covidien Allegedly Paid Hospitals Each Time They Used Solitaire

Covidien paid $13 million to resolve civil allegations involving its Solitaire mechanical thrombectomy device, which retrieves blood clots and restores blood flow in certain stroke patients. The Justice Department’s December 2018 announcement describes a registry launched after FDA clearance.

The government alleged that, for about two years beginning in August 2014, Covidien paid participating hospitals and institutions a fee each time they used a new Solitaire device and reported specified clinical data. The government alleged that Covidien recruited institutions to switch from competing products or continue using its products, and used the registry to increase sales.

Here the institution received the enrollment payment. The alleged inducement reached the facility buying and using the device, with Medicare and Medicaid claims following the procedures. A former Covidien employee brought the whistleblower case. The payment ledger, registry enrollment and account’s purchasing history describe different sides of the same institutional relationship.

Innovasis Put Registry Payments Beside Other Surgeon Benefits

The 2024 Innovasis civil settlement totaled $12 million and covered allegations that the spinal-device manufacturer paid surgeons to use its products in procedures on Medicare patients. The government described registry payments alongside consulting fees, intellectual-property payments, performance shares, travel and entertainment.

The allegations about work were concrete. Innovasis allegedly paid excessive consulting rates and sometimes paid for work never performed. It also allegedly bought or licensed intellectual property without obtaining a valuation, then failed to use it for meaningful product development.

The whistleblower’s complaint described spreadsheets comparing surgeon compensation with product use. Those allegations concerned the company’s intellectual-property, royalty and consulting arrangements. The complaint described what happened when the sales disappointed:

That alleged response supplies a useful comparison for someone reviewing research payments: what performance did management measure, and what caused it to stop paying?

Olympus Held the Research Grant Until the Purchase

Olympus Corp. of the Americas agreed to pay $310.8 million to settle civil claims concerning kickbacks that caused false claims to Medicare, Medicaid and TRICARE. The March 2016 announcement describes how grants and free equipment helped the company win business.

Olympus agreed that the government’s criminal complaint was true. The complaint described the company giving one hospital a $5,000 grant to facilitate a $750,000 sale. It held up a $50,000 research grant until another hospital signed an agreement to buy Olympus equipment. A physician with a major role in a medical center’s purchasing decisions also received free use of equipment in a private practice.

The research money waited for a purchase agreement. Buying the equipment was what released it. The free equipment shows why the comparison also reaches benefits outside the research ledger: the person influencing the institution’s purchase could receive value somewhere else.

What Evidence Is Needed to Prove Fraud?

For a device research-payment case, the evidence connects the benefit, the intended product choice, the company’s knowledge and the resulting government claim. We work through that connection with the insider who understands how the study and the account operated.

We examine why the company chose an investigator, what work the payment bought and which product choices and government claims followed.

An enrollment manager may understand the data submitted. A sales representative may understand the recruiting decisions. A provider’s records may complete the connection to the procedure and claim. We bring those perspectives together around the particular arrangement.

How Is Healthcare Fraud Detected?

In device research arrangements, detection starts with the gap between the payment’s stated purpose and what happened inside the business. CMS Open Payments publishes the manufacturer’s description of a transfer. An insider may know that the reported work never happened or that management measured the recipient’s purchases instead.

Published payment analyses describe recipients and payments. We bring your knowledge of the arrangement together with the study and sales records to establish why the company paid, what decision it sought and which government-paid procedures followed.

How Does Reimbursement Work for Medical Devices?

Most implanted devices sit inside the hospital’s payment for the procedure or stay. The surgeon may choose the brand while the institution buys the device and bills Medicare. That separation helps explain why a manufacturer would direct payments at someone who influences purchasing without personally buying the implant.

A hospital may report device codes and charges while receiving payment that includes the device’s cost in the procedure rate. The clinical and purchasing records identify the product used. The claim shows the procedure billed to the government. We connect both to the manufacturer payment and the decision it was intended to influence.

The Medtronic and Covidien allegations followed that manufacturer-to-provider connection: payments intended to drive device use allegedly caused providers to submit false claims. The enrollment payment was the beginning of the claimed scheme. The government-funded procedure supplied the financial consequence.

Registries Required for Medicare Coverage

Medicare can require registry participation for coverage, as it does for transcatheter aortic valve replacement. For an insider in a manufacturer-funded registry, we examine what clinical work the program required alongside what the manufacturer paid investigators to do. The St. Jude and Medtronic announcements describe actual data collection alongside the alleged effort to buy product choices.

Whistleblower Cases Over Research Payments

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The device registry cases show insiders bringing these arrangements to light: a former employee brought the Covidien qui tam case, and a former regional sales director brought the Innovasis case.

Someone responsible for enrollment, research operations, payments or an account relationship may understand a connection that the contract alone leaves out. Our work starts with that knowledge and follows it through the product choice to the provider’s claims.

When the Study File and Sales File Tell Different Stories

If you know why an investigator was selected or what a registry payment actually bought, tell our whistleblower experts what the research agreement left out. We turn that inside knowledge into a case connecting the payments, product choices and government claims, and bring in medical device whistleblower lawyers who understand research-payment kickbacks. You have us beside you from the first conversation through the case.